Q-Line Biotech Ltd IPO — Broker Reviews

Strong growth in revenue and consistent profitability in the diagnostics segment. However, high debt levels and SME listing risk should be considered.

The company benefits from growing demand in the IVD sector with strong product diversification. Valuation appears reasonable at upper price band.

Stable business model with moderate margins. High borrowing and SME volatility keep risk elevated.

Strong distribution network and diversified diagnostics portfolio support long-term growth potential in healthcare sector.

Fairly valued IPO with decent fundamentals, but limited upside due to competitive pressures in diagnostic industry.